Drug Trial Radar · NCT02503644
Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis
Last checked: Nov 19, 2026Latest source record: Mar 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
145
Actual
Start
Oct 29, 2015
Primary completion
Oct 2018
Study completion Oct 12, 2018
Sponsor
- Lead sponsor
- Inventiva PharmaIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Systemic sclerosis (SSc), or scleroderma is a connective tissue disease of autoimmune origin. It is a life-threatening orphan disease with severe physical and psychosocial consequences. IVA337 has a novel mechanism of action and this study is designed to compare IVA337 at two dose levels with a placebo control treatment. Patients will be unaware of the treatment they are receiving and will be randomized to one of three treatment arms , either IVA337 400mg bid, IVA337 600mg bid or placebo bid. They will receive drug for 48 weeks and during that time assessments will be made to monitor both the efficacy and safety of the treatment.
Conditions
- Scleroderma, Diffuse
- Diffuse Cutaneous Systemic Sclerosis
Interventions
IVA337Drug
Capsules of 200mg IVA337
PlaceboDrug
Identical capsules without active substance
Primary outcomes
What the sponsor says the trial is designed to measure.
- Measurement of skin thickness by the Modified Rodnan Skin Score (MRSS)Time frame: 48 weeks
Locations
49 sites in 10 countries. Site status is shown where the registry gives one.
University Multiprofile Hospital for Active Treatment - Dr. Georgi Stranski
Pleven, Bulgaria
Multiprofile Hospital for Active Treatment Plovdiv
Plovdiv, Bulgaria
University Multiprofile Hospital for Active Treatment -Kaspela
Plovdiv, Bulgaria
University Multiprofile Hospital for Active Treatment - "Sveti Ivan Rilski"
Sofia, Bulgaria
Hôpital Pellegrin
Bordeaux, France
CHRU de Lille- Hôpital Claude Huriez
Lille, France
Hopital Cochin
Paris, France
University Hospital of Strasbourg
Strasbourg, France
Kerckhoff-Klinik
Bad Nauheim, Germany
Charité- Universitätsmedizin Berlin
Berlin, Germany
Chaité-Universtätsmedezin Berlin
Berlin, Germany
Klinik fur Dermatologie und Venerologie der Universitat zu Köln
Cologne, Germany
Univertaetsklinikum Carl Gustav Carus
Dresden, Germany
University of Erlangen-Nuremberg
Erlangen, Germany
CIRI GmbH Centrum für Innovative Diagnostik und Therapie
Frankfurt, Germany
University Medical Center Freiburg
Freiburg im Breisgau, Germany
Kilinik für Hautkrankenheiten
Münster, Germany
Universtätsklinik Ulm
Ulm, Germany
Istituto di Clinica Medica Generale Polo Didattico
Ancona, Italy
Azienda Ospedalaria Spedali Civili di Brescia
Brescia, Italy
Azienda Ospedaliera Universitaria Careggi
Florence, Italy
Ospedale San Salvatore ASL L'Aquila
L’Aquila, Italy
Azienda Ospedaliera Universitaria Federico II
Naples, Italy
University of Padova
Padova, Italy
Ospedale di Alta Specializzazione "San Camillo"
Roma, Italy
Policlinico Umberto I
Roma, Italy
Universita degli Studi de Verona
Verona, Italy
Leiden University Medical Center
Leiden, Netherlands
Erasmus MC Universitair Medisch Centrum Rotterdam
Rotterdam, Netherlands
Centrum Miriada Prywatny
Bialystok, Poland
University Hospital in Bydgoszcz
Bydgoszcz, Poland
CM Plejady
Krakow, Poland
Reumed
Lublin, Poland
Medycine Centrum Hetmanska Poznan
Poznan, Poland
Centrum Medyczne Oporow
Wroclaw, Poland
University Medical centre Ljubljana
Ljubljana, Slovenia
University Medical Centre Maribor
Maribor, Slovenia
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hopital Universitario Gregorio Marañon
Madrid, Spain
Hopital 12 de Octubre
Madrid, Spain
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.